A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum

Simply Wall St.01-23

AdvertisementRecent performance snapshot and what it might mean for investors Charles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605476802?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-01-23 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605476802","market":"sg","top_or_hot":-1,"title":"A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent performance snapshot and what it might mean for investors Charles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent performance snapshot and what it might mean for investors Charles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1815336091.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec","article_id":"2605476802","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605476802","pubTimestamp":1769151141,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent performance snapshot and what it might mean for investors\nCharles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing at $224.03 and showing mixed short term moves alongside stronger returns over the past year.\nOver the past month, the stock return is 10.43%. The past 3 months show a 13.70% gain, and the 1 year total return stands at 34.26%. Short term performance is more muted, with a 0.25% move over the past week and a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4530":"医药外包概念","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","CRL.AU":"Comet Resources Ltd","CRL":"查尔斯河","BK4121":"生命科学工具和服务","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK7095":"多种金属与采矿","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC"},"translate_title":"查尔斯河实验室(CRL)近期股价势头后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5,"CRL.AU":1.5},"content_text":"AdvertisementRecent performance snapshot and what it might mean for investors Charles River Laboratories International (CRL) has drawn investor attention after recent trading, with the stock closing at $224.03 and showing mixed short term moves alongside stronger returns over the past year. Over the past month, the stock return is 10.43%. The past 3 months show a 13.70% gain, and the 1 year total return stands at 34.26%. Short term performance is more muted, with a 0.25% move over the past week and a 1.21% decline on a 1 day basis. See our latest analysis for Charles River Laboratories International. For Charles River Laboratories International, a firm year long total shareholder return of 34.26% alongside a 10.43% 1 month share price return suggests momentum has been building recently, even though the 3 year and 5 year total shareholder returns remain negative. If you are comparing CRL with other healthcare names, this could be a good moment to widen your watchlist and look at healthcare stocks as further ideas. With CRL trading at $224.03, sitting above the average analyst price target yet showing an intrinsic discount estimate of 18.03%, you need to ask yourself whether there is still a buying opportunity here or whether future growth is already priced in. Most Popular Narrative: 18.6% Overvalued Based on the most followed narrative, Charles River Laboratories International has a fair value estimate of $188.93 compared with the current share price of $224.03, which implies the stock is trading above that narrative value.  The analysts have a consensus price target of $177.067 for Charles River Laboratories International based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $211.0, and the most bearish reporting a price target of just $151.0.  Read the complete narrative. Want to understand why this popular view still sees upside in earnings, margins and valuation multiples, even with today’s price where it is? The full narrative spells out how modest top line growth, a margin rebuild and a higher future earnings multiple come together to support that fair value. Curious which of those levers does most of the heavy lifting in the model, and how sensitive the outcome is to small changes in the assumptions? Result: Fair Value of $188.93 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh risks such as weaker DSA demand and faster adoption of non animal testing, which could pressure future revenue and margins. Find out about the key risks to this Charles River Laboratories International narrative. Another view: market multiples tell a different story While the most followed narrative sees Charles River Laboratories International as 18.6% overvalued versus a $188.93 fair value, our multiples check points in another direction. On a P/S of 2.7x, CRL sits below the US Life Sciences average of 3.8x, the peer average of 5.2x, and our fair ratio of 2.9x. This gap suggests the recent share price already bakes in some caution, despite the narrative calling the stock overvalued. The key question is whether you think the business moves closer to the fair ratio over time or remains priced at a discount. See what the numbers say about this price — find out in our valuation breakdown. NYSE:CRL P/S Ratio as at Jan 2026 Build Your Own Charles River Laboratories International Narrative If you interpret the numbers differently or prefer to rely on your own analysis, you can test your assumptions and build a custom view in minutes by starting with Do it your way. A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you stop at just one company, you miss the bigger picture, so use the Simply Wall St Screener to quickly spot fresh opportunities that match your style.  Hunt for potential value by checking out these 879 undervalued stocks based on cash flows that some investors might be overlooking right now. Zero in on future tech themes by scanning these 24 AI penny stocks that are tied to artificial intelligence trends. Strengthen your income focus by reviewing these 12 dividend stocks with yields > 3% that already offer yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605476802","isCrawlerRequest":true}